Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers.

We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.

But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?

Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!